May 18, 2006 – Merck won the endorsement of an FDA scientific advisory board for Gardasil, its vaccine for HPV; GPC Biotech said the data monitoring committee will conduct an interim review of the satraplatin data; SFBC has been given 60 days to file for a permit to demolish its Miami facility; an FDA advisory board has recommended approval for Exelon from Novartis; Alfacell will begin a clinical trial of Onconase against mesothelioma; Ceragenix said its Ceragenin compound was 100 times more effective against staph infection than vancomycin; Coley Pharma received Fast Track designation for Actilon; and BioVeris was the recipient of a strong, though mysterious, buying surge late in the day. The Centient Biotech 200™ fell 62 points to 3574.19, a loss of 1.69%. More details...
